HPS-4/TIMI 65/ORION-4

ORION Design 2018-02-05 for TIMI Website

HPS-4/TIMI 65 ORION-4 will examine the effects of inclisiran, a small interfering RNA (siRNA) that inhibits the synthesis of PCSK9, on cardiovascular outcomes among individuals with atherosclerotic cardiovascular disease. It will be conducted at high-enrolling sites using a streamlined, quality-by-design approach.

ORION on ClinicalTrials.gov

CONTACT US About ORION

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close